Drug Trial Radar · NCT04314544
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)
Last checked: Nov 19, 2026Latest source record: Jan 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
508
Actual
Start
Jul 1, 2020
Primary completion
Mar 26, 2025
Study completion Dec 22, 2025
Sponsor
- Lead sponsor
- Sun Pharmaceutical Industries LimitedIndustry
- Sponsor type
- Industry
- First posted
- Mar 19, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter Phase III, Randomized, Double-Blind, Single-Dose, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of tildrakizumab in Subjects with Active Psoriatic Arthritis I (INSPIRE 1)
Conditions
- Active Psoriatic Arthritis
Interventions
TILDDrug
one 1 mL injection of study medication
matching placebo injectionsDrug
one 1 mL injection of placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- The proportion of subjects who achieve American College of Rheumatology [ACR20]Time frame: at week 24
Locations
97 sites in 12 countries. Site status is shown where the registry gives one.
Sunpharma Site no 42
Dothan, Alabama
Sunpharma Site no 29
Gilbert, Arizona
Sunpharma Site no 30
Glendale, Arizona
Sunpharma Site no 31
Mesa, Arizona
Sunpharma Site no 35
Covina, California
Sunpharma Site no 48
Encino, California
Sunpharma site no. 17
Fountain Valley, California
Sunpharma site no. 15
Thousand Oaks, California
Sunpharma Site no. 141
Avon Park, Florida
Sunpharma site no. 21
Clearwater, Florida
Sunpharma site no. 02
Hialeah, Florida
Sunpharma Site no 55
Kissimmee, Florida
Sunpharma Site no. 75
Margate, Florida
Sunpharma site no. 05
New Port Richey, Florida
Sunpharma Site no. 76
Ocoee, Florida
SunPharma Site no 22
Tamarac, Florida
Sunpharma Site no 46
Gainesville, Georgia
Sunpharma Site no 41
Oak Brook, Illinois
Sunpharma Site no 54
Orland Park, Illinois
Sunpharma Site no 38
Schaumburg, Illinois
Sunpharma Site no 37
Skokie, Illinois
Sunpharma Site no. 122
Skokie, Illinois
Sunpharma site no. 20
Wichita, Kansas
Sunpharma site no. 07
Worcester, Massachusetts
Sunpharma site no. 14
Springfield, Missouri
Sunpharma Site no 53
Kalispell, Montana
Sunpharma Site no 27
Lincoln, Nebraska
Sunpharma Site no 44
Voorhees Township, New Jersey
Sunpharma Site no 52
Charlotte, North Carolina
Sunpharma Site no. 73
Leland, North Carolina
Sunpharma Site no 56
Wilmington, North Carolina
Sunpharma Site no 33
Minot, North Dakota
Sunpharma site no. 11
Middleburg Heights, Ohio
Sunpharma Site no. 124
Oklahoma City, Oklahoma
Sunpharma Site no 34
Greenville, South Carolina
Sunpharma Site no 50
Austin, Texas
Sunpharma site no. 13
Baytown, Texas
Sunpharma Site no 49
Colleyville, Texas
Sunpharma site no. 08
Houston, Texas
Sunpharma Site no 28
Lubbock, Texas
Showing 40 of 97 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.